News | February 19, 2024
GSK completes acquisition of Aiolos Bio
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated
